Jeffrey Switchenko

27PUBLICATIONS
155CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer geneticsMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jul 08, 2026
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.

|Feb 17, 2026
Receipt of guideline-concordant local and chemotherapy-based systemic therapy for patients with triple-negative breast cancer: 10-year survival outcomes in a multi-state population-based analysis.

Joseph Lipscomb, Gretchen G Kimmick, J Frank Wilson

|May 12, 2025
Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer.

Nicole C Schmitt, William A Stokes, James E Bates

|Jul 07, 2023
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.

Chloe S Lalonde, Jeffrey M Switchenko, Madhusmita Behera

|Feb 22, 2023
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.

Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko

|Dec 16, 2022
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.

Pamela B Allen, Ashley A McCook-Veal, Jeffrey M Switchenko

Pageof 5

Frequent Collaborators

6 joint publications

Jonathon Cohen

6 joint publications

Brad S Kahl

4 joint publications

Rajesh Valanparambil

4 joint publications

Mehul S Suthar